Clarus — 2016 Investments
6 investments dated 2016 · listed companies and verified rows first · show all
BiotechLa Jolla, US
Eric W. Roberts(Executive Officer, Director)Kenneth A. Stauderman(Executive Officer)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Sudarshan Hebbar(Executive Officer)Michael J. Dunn(Executive Officer)
Board seatEmmett Cunningham· per SEC Form D · $80.4M raise · filed Jun 2018
Co-investorsSanderling VenturesOrbiMed
Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.
BiotechCambridge, US
Kiran Reddy(Executive Officer, Director)
Board seatNicholas GalakatosNicholas G. Galakatos· per SEC Form D · $10M raise · filed Jun 2019
Co-investorsOCV PartnersVida Ventures
BiotechVancouver
Frank Perabo(Executive Officer)Franklin Berger(Director)Raymond Andersen(Executive Officer, Director)Scott Requadt(Director)Paul Cossum(Executive Officer)David Wood(Executive Officer)
Board seatScott Requadt· per SEC Form D · $15M raise · filed Jan 2016
Co-investorsOmega Funds
HealthtechMt Olive, US
Louis Altieri(Executive Officer)Larry Heaton(Executive Officer)
BoardSteven C. Adler(Director)David Jenkins(Director)Donald P. Carson(Director)
Board seatKurt Wheeler· per SEC Form D · $15M raise · filed Jun 2016
Tectonic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that target G-Protein Coupled Receptors (GPCRs) using a proprietary platform called GEODe™.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Timothy A. Springer(Co-Founder)Andrew C. KruseTimothy Springer(Director)Andrew Kruse(Director)Alise Reicin(Executive Officer, Director)Daniel Lochner(Executive Officer)
Board seatScott Requadt· per SEC Form D · $25M raise · filed Aug 2016
Co-investorsEcoR1 CapitalVida VenturesAlly Bridge GroupPolaris PartnersSoleus Capital
BiotechCambridge, US
DAVID ANDERSON(CHIEF SCIENTIFIC OFFICER)JAMES MARTIN(CHIEF FINANCIAL OFFICER)CURT LOCKSHIN(CHIEF TECHNOLOGY OFFICER)JEFF BAXTER(CHIEF EXECUTIVE OFFICER AND PRESIDENT)Gary Robertson(Director)Carlos H. Fernandez-Mazzi(Director)
Board seatScott Requadt· per SEC Form D · $7M raise · filed Dec 2018
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.